A biomimetic approach for enhancing the in vivo half-life of peptides.
- Citation data:
Nature chemical biology, ISSN: 1552-4469, Vol: 11, Issue: 10, Page: 793-8
- Publication Year:
- Repository URL:
- https://works.bepress.com/andreas-franz/57; https://scholarlycommons.pacific.edu/cop-facarticles/117
- Biochemistry, Genetics and Molecular Biology; drug delivery; peptides; pharmacology; chemical synthesis; Chemistry
- Most Recent Tweet View All Tweets
The tremendous therapeutic potential of peptides has not yet been realized, mainly owing to their short in vivo half-life. Although conjugation to macromolecules has been a mainstay approach for enhancing protein half-life, the steric hindrance of macromolecules often harms the binding of peptides to target receptors, compromising the in vivo efficacy. Here we report a new strategy for enhancing the in vivo half-life of peptides without compromising their potency. Our approach involves endowing peptides with a small molecule that binds reversibly to the serum protein transthyretin. Although there are a few molecules that bind albumin reversibly, we are unaware of designed small molecules that reversibly bind other serum proteins and are used for half-life extension in vivo. We show here that our strategy was effective in enhancing the half-life of an agonist for GnRH receptor while maintaining its binding affinity, which was translated into superior in vivo efficacy.